Chris Shibutani
Stock Analyst at Goldman Sachs
(3.52)
# 873
Out of 5,147 analysts
95
Total ratings
55.1%
Success rate
21.15%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $61.74 | +61.97% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $13.66 | -78.04% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $8.74 | +71.62% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $30.10 | +6.31% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $110.23 | +24.29% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $21.71 | +52.00% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $503.90 | -40.07% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $46.21 | +10.37% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $248.43 | -37.61% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $15.17 | -73.63% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $7.29 | +174.35% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,051.99 | -31.27% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $12.06 | +115.59% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $132.25 | +15.69% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $232.08 | -25.46% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $68.98 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $62.37 | +10.63% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $22.96 | -43.38% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $102.02 | -77.46% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $13.97 | +257.91% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $91.35 | -43.08% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $27.65 | +117.00% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $11.93 | +50.88% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $11.14 | +52.60% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.55 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.70 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $61.74
Upside: +61.97%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $13.66
Upside: -78.04%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $8.74
Upside: +71.62%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $30.10
Upside: +6.31%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $110.23
Upside: +24.29%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $21.71
Upside: +52.00%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $503.90
Upside: -40.07%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $46.21
Upside: +10.37%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $248.43
Upside: -37.61%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $15.17
Upside: -73.63%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $7.29
Upside: +174.35%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,051.99
Upside: -31.27%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $12.06
Upside: +115.59%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $132.25
Upside: +15.69%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $232.08
Upside: -25.46%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $68.98
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $62.37
Upside: +10.63%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $22.96
Upside: -43.38%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $102.02
Upside: -77.46%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $13.97
Upside: +257.91%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $91.35
Upside: -43.08%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $27.65
Upside: +117.00%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $11.93
Upside: +50.88%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $11.14
Upside: +52.60%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.55
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.70
Upside: -